Drugs / Nicotine Replacement
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial | ||||||
| — | NCT03808818 | Aug 2019 → Dec 2023 | in situ carcinoma | ECOG-ACRIN Cancer Research Group | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 0 | NCT02582008 Comparator | Jan 2016 → Oct 2018 | hypopharynx squamous cell carcinoma, laryngeal squamous cell carcinoma, nasopharyngeal carcinoma, oral cavity squamous cell carcinoma +1 | Wake Forest University Health Sciences | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nicotine Replacement | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03808818 ↗ |
| Route | Oral | “Given NRT patch or lozenge (or both)” NCT03808818 ↗ |
| Route | Topical | “Given NRT patch or lozenge (or both)” NCT03808818 ↗ |